Compare Abeona Therapeutics Inc (ABEO) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Kinder Morgan Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Kinder Morgan Inc trades at $32.36 (market cap $72.28B). The key difference: Kinder Morgan Inc is far larger — about 193.6× Abeona Therapeutics Inc's market cap, and Kinder Morgan Inc pays a 3.62% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KMI | |
|---|---|---|
Market Cap | $373.32M | $72.28B |
Sector | Health | Energy |
52-Week High | $7.23 | $34.31 |
52-Week Low | $4.17 | $25.84 |
Enterprise Value | $228.22M | $104.16B |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
KMI trades at $32.49, up 1.34% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and maintains a solid dividend of $0.30 per share. Revenue grew to $16.94B in 2025, with net income reaching $3.06B, reflecting an 18.04% margin. Analyst consensus is mixed, with 47% buy ratings and 50% hold.
KMI's outlook is supported by stable cash flows from fee-based contracts and a $10.1B project backlog focused on natural gas infrastructure. Key risks include high debt levels and exposure to energy market volatility. The stock offers income potential with a near 4% yield, but investors should monitor execution on growth projects and commodity price trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
